.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
UBS
Cantor Fitzgerald
Chinese Patent Office
Fuji
Colorcon
Teva
Novartis
Baxter

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017651

« Back to Dashboard
NDA 017651 describes HEPARIN SODIUM, which is a drug marketed by Hospira, Sandoz, Solopak, Watson Labs Inc, West-ward Pharms Int, Sagent Pharms, Lilly, Gland Pharma Ltd, Fresenius Kabi Usa, Chamberlin Parenterl, Abraxis Pharm, Shenzhen Techdow, Smith And Nephew, Dell Labs, Parke Davis, Luitpold, Organon Usa Inc, Watson Labs, Pfizer, Pharmacia And Upjohn, Hospira Inc, Pharm Spec, Akorn, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny, and is included in fifty-eight NDAs. It is available from twelve suppliers. Additional details are available on the HEPARIN SODIUM profile page.

The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

Summary for 017651

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 017651

Ingredient-typeHeparin

Suppliers and Packaging for NDA: 017651

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HEPARIN SODIUM
heparin sodium
INJECTABLE;INJECTION 017651 NDA Fresenius Kabi USA, LLC 63323-047 63323-047-10 25 VIAL in 1 TRAY (63323-047-10) > 10 mL in 1 VIAL

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength10,000 UNITS/ML
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Summary for product number 005

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength1,000 UNITS/ML
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Summary for product number 006

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength5,000 UNITS/ML
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Citi
Mallinckrodt
US Army
AstraZeneca
Queensland Health
QuintilesIMS
Moodys
Fuji
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot